Such an approach could involve pharmacological therapy, where it would be feasible to inhibit CDA1’s pathological activity to treat established DKD, thus slowing down, arresting or reversing the progression of established DKD. The gene discussed is TSPYL2; the disease is diabetic kidney disease.